I'M DEFINATELY HOLDING TILL 1998. I SEE MANY INTERESTING POSSIBILITIES IN THE NEXT FIVE MONTHS. PROCEPT SHOULD BE ABLE TO OBTAIN A PARTNERSHIP FOR THEIR TROPICAL MICROBICIDE. I ALSO BELIEVE THEY WILL FIND A PARTNER FOR THEIR IMMUNOSUPPRESSIVE THERAPY PROGRAM. THE PHASE I RESULTS FOR THE ENGLAND STUDY SHOULD BE ANNOUNCED (SHOULD BE POSITIVE) AND A PRIVATE PLACEMENT FOR ADDITIONAL CASH.
I FOUND A REFERENCE BY A COMPANY CALLED ROBERTS, SHERIDAN & KOTEL THAT THEY HAVE REPRESENTED PARAMOUNT CAPITAL IN CONNECTION WITH PRIVATE OFFERINGS OF PREFERRED STOCK FOR THE FOLLOWING BIOTECHNOLOGY COMPANIES:
1. ZONAGEN, INC.
2. XYTRONYX, INC.
3. BOSTON LIFE SCIENCES
4. SPARTA PHARMACEUTICALS, INC.
I HIGHLY RECOMMEND THAT YOU LOOK AT ZONAGEN (COMPARISON WITH PROCEPT ONLY, NOT TO BUY). ZONAGEN DEVELOPS TREATMENTS FOR HUMAN REPRODUCTIVE DISORDERS. PRODUCT DEVELOPMENT FOCUSES ON FERTILITY, CONTRACEPTIVES, AND DEVELOPING VASOMAX, AN ORAL PILL TREATMENT FOR MALE IMPOTENCY. THE COMPANY ALSO CONDUCTS RESEARCH IN OTHER AREAS OF REPRODUCTIVE HEALTH CARE, SUCH AS PREVENTION OF SEXUALLY TRANSMITTED DISEASES, THE DETECTION AND TREATMENT OF ENDOMETRIOSIS, AND THERAPIES TO TREAT PROSTATE CANCER. THE COMPANY HAS SALES OF $3.3 MILLION IN 1996, 35 EMPLOYEES, 7.377 MILLION SHARES OUTSTANDING, AND LOCATED IN THE WOODLANDS, TEXAS. IN OCTOBER OF 1996, ZONAGEN COMPLETES A $16.9 MILLION PRIVATE PLACEMENT OF SERIES B CONVERTIBLE PREFERRED. THE STOCK PRICE WENT FROM APPROXIMATELY $8.00 TO $25.00 SINCE THEN. IN MAY OF THIS YEAR, ZONAGEN SAID IT RECEIVED POSITIVE RESULTS FROM A PHASE III CLINICAL TRIAL OF VASOMAX, A THERAPY FOR ERECTILE DYSFUNCTION. THE DRUG IS TAKEN ORALLY "ON DEMAND" ZONA STATED THAT IST PLANS TO SUBMIT A NEW DRUG APPLICATION TO THE FOOD AND DRUG ADMINISTRATION "AS SOON AS POSSIBLE." SIMULTANEOUSLY, ZONA WILL USE THE TRIAL DATA IN NEGOTIATIONS FOR GLOBAL MARKETING AGREEMENTS WITH SEVERAL "MAJOR" PHARMACEUTICAL COMPANIES. ON THE ANNOUNCEMENT THE STOCK PRICE INCREASED ABOUT $7.00.
|
